医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China

2020年02月21日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan: “Meiji”) announced today that Meiji decided a financial donation to support coronavirus outbreak control in China.

Daikichiro Kobayashi, President and Representative Director said “First of all, we extend our sincerest condolences to the victims and their families. For about 30 years, we have been operating its business in Guangdong and Shandong, and we greatly appreciate the customers and partners all over in China. We would like to give our support to everyone there and hope our donation helps.”

We sincerely pray for early recovery of Novel coronavirus associated pneumonia patients and the end of virus infection in China.

Details of the donation
- Amount of contribution: RMB 1 million (approximately JPY 16 million)
- Donated to: Red Cross Society of China

View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005336/en/

CONTACT

Beijing Office: (010)65388196

Zhao Chengguo

https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作